Activities of ceftazidime and avibactam against β-lactamase-producing enterobacteriaceae in a hollow-fiber pharmacodynamic model

Avibactam is a novel non-β-lactam β-lactamase inhibitor that is currently undergoing phase 3 clinical trials in combination with ceftazidime. Ceftazidime is hydrolyzed by a broad range of β-lactamases, but avibactam is able to inhibit the majority of these enzymes. The studies described here attempt to provide insight into the amount of avibactam required to suppress […]

Read More
Learn More